+34 679 490 537info@nanbiosis.com

Nanbiosis

U1. Protein Production Platform Unit (PPP)

Ciber bbn

U1. Protein Production Platform (PPP)

U1. PPP logo IBB UAB

Order request

Description

The PPP Unit is at the Institute of Biotechnology and biomedicine of the Autonomous University of Barcelona (IBB-UAB) and counts with the necessary facilities for the design, production and purification of recombinant proteins. This facility is coordinated by the Nanobiotechnology Group, leaded by Prof. Antonio Villaverde. It has both highly specialized personnel and the necessary equipment to offer an “tailored” service for the design, production and purification of recombinant proteins using both prokaryotic and eukaryotic expression systems. Its location allows this service to be linked with other complementary services available within the university (Cell Culture, Cytometry, Production of Antibodies, Microscopy, Proteomic, and Bioinformatic,X-ray crystallography, and the Microarray and Sequencing Services), as well as facilitating the management of subsequent uses of the produced protein.

Counts with a laboratory perfectly equipped for the bioproduction of proteins, other with all the necessary equipment for the molecular cloning, plus one lab for the purification and characterization, and finally one for cryopreservation.

The PPP Unit is also applying for the ISO9001 certification forstandard quality control system.

IQNet ISO 9001:2015 Certification PPP

AENOR ISO 9001:2015 Certification PPP

Active projects

Title Fundin: Organism Call: Funding source Role
GA: 720942 SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry Unión Europea (Comisión Europea) H2020-NMBP-2016-2017 Coordinator
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Other projects

Ref Title Funding Organism Unit Role
PI15/00272 Design of intelligent nanoconjugates for the treatment of metastatic colorectal cancer. Instituto de Salud Carlos III Participant
BIO2013-41019-P ENGINEERING OF PROTEIN NANOPARTICLES FOR THE DIRECT DELIVERY OF THERAPEUTIC PROTEINS AND NUCLEIC ACIDS MINECO Participant
2014SGR-132 Basic and Applied Microbiology AGAUR Participant
BIO2016-76063-R DEVELOPMENT OF NONOSTRUCTURED PROTEIN TOXINS AND POISONS FOR THE TREATMENT OF CXCR4 + CANCERES MINECO Working package
RTC-2014-2207-1 TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases MINECO Participant
Marato 416/C/2030TV32013-132031 Genotoxic nanoparticles targeting colorectal cancer stem cells Marato TV3 Participant

Publications


2016

  • Corchero J.L.. Eukaryotic aggresomes: from a model of conformational diseases to an emerging type of immobilized biocatalyzers. Applied Microbiology and Biotechnology. 2016;100(2):559-569.
  • Saccardo P., Corchero J.L., Ferrer-Miralles N.. Tools to cope with difficult-to-express proteins. Applied Microbiology and Biotechnology. 2016;:1-9.
  • Torrealba D., Seras-Franzoso J., Mamat U., Wilke K., Villaverde A., Roher N. et al. Complex particulate biomaterials as immunostimulant-delivery platforms. PLoS ONE. 2016;11(10)
  • Cano-Garrido O., Sanchez-Chardi A., Pares S., Giro I., Tatkiewicz W.I., Ferrer-Miralles N. et al. Functional protein-based nanomaterial produced in microorganisms recognized as safe: A new platform for biotechnology. Acta Biomaterialia. 2016;43:230-239.
  • Serna N., Cespedes M.V., Saccardo P., Xu Z., Unzueta U., Alamo P. et al. Rational engineering of single-chain polypeptides into protein-only, BBB-targeted nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine. 2016;12(5):1241-1251.
  • Rueda F., Gasser B., Sanchez-Chardi A., Roldan M., Villegas S., Puxbaum V. et al. Functional inclusion bodies produced in the yeast Pichia pastoris. Microbial Cell Factories. 2016;15(1)
  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
  • Céspedes MV, Unzueta U, Álamo P, Gallardo A, Sala R, Casanova I et al. Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4+ colorectal cancer models.Nanomedicine : nanotechnology, biology, and medicine. 2016;12(7)
  • Giannotti M.I., Abasolo I., Oliva M., Andrade F., Garcia-Aranda N., Melgarejo M. et al. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS Applied Materials and Interfaces. 2016;8(39):25741-25752.

News U1

18 Apr

Collaboration of two NANBIOSIS units in the Valorisation Project “ADVERT”

The Project ADVERT (Advanced Extracellular Vesicles for Enzyme Replacement Therapy) is a research valorisation project recently granted by CIBER. The project pursues to advance the development of extracellular vesicles as treatments for lysosomal diseases, specially to bring new therapies to treat FABRY disease. The ADVERT Project will count on the active particpation of two NANBIOSIS units of CIBER-BBN: Unit 20 of the ICTS NANBIOSIS at Vall d’Ebrón Hospital, led by Ibane Abasolo, who coordinates the project. Unit 1 Protein Production Platform (PPP), at the IBB-UAB, led by Neus Ferrer, throught the coordination in the project of José Luis Corchero. T[...]

26 Feb

A more effective nanomedicine has been developed for the treatment of Fabry rare disease.

28 February: International Rare Disease Day This is one of the major achievements of the European Smart4Fabry project, which is now coming to an end after four years of work.The results have been made possible by nanotechnology and the approach developed could be applied to other drugs in the future.The new drug improves on current treatments and helps reduce costs and improve patients’ quality of life. Barcelona, 26 February 2021.- The advance of nanomedicine opens up new possibilities in the development of drugs, such as the one recently developed for the rare disease Fabry, with improved efficacy compared to existing[...]

25 Feb

An Auristatin-based nanoconjugate reduces leukemia burden in a disseminated AML model

Researchers of the Nanotoxicology Unit of the the CIBER-BBN ICTS NANBIOSIS (u18-nanotoxicology-unit), leaded by Ramon Mangues and Isolda Casanova at the Research Institute of the Hospital de Sant Pau and of the NANBIOSIS (nanbiosis.es) Protein Platform (u1-protein-production-platform-ppp) leaded by Antonio Villaverde and Neus Ferrer Miralles of the Institute of Biotechnology and Biomedicine at the Autonomous University of Barcelona, have developed a novel protein-Auristatin nanoconjugate that specifically targets CXCR4-overexpressing acute myeloid leukemia (AML) cells. It selectively accumulates in target cancer cells expressing this receptor and deliver the toxin Auristatin within their cytosol. There, Auristatin potently blocks microtubule polymerization, provoking mitotic catastrophe,[...]

21 Feb

A nanotoxin targeting the receptor CXCR4 blocks lymphoma dissemination

Researchers at the Nanotoxicology Unit of CIBER-BBN ICTS NANBIOSIS (u18-nanotoxicology-unit), led by Ramon Mangues and Isolda Casanova of the Research Institute at the Hospital de Sant Pau and the Researchers of the NANBIOSIS (nanbiosis.es) Protein Production Platform (u1-protein-production-platform-ppp) led by Antonio Villaverde and Neus Ferrer Miralles of the Institute of Biotechnology and Biomedicine at the Autonomous University of Barcelona, have participated in the development of a novel protein nanoparticle that incorporates the Exotoxin of the bacteria Pseudomonas aeruginosa, capable of targeting lymphoma cells that overexpress the CXCR4 receptor. They internalize selectively in target cancer cells through CXCR4 receptor-mediated endocytosis du[...]

15 Feb

Identification of a novel nanotherapy active in cancer cells resistant to chemotherapy

Researchers of the Nanotoxicology Unit (u18-nanotoxicology-unit) led by Ramon Mangues and Isolda Casanova at the Research Institute of the Hospital de Sant Pau and the Protein Production Platform (u1-protein-production-platform-ppp), led by Antonio Villaverde and Neus Ferrer Miralles of the Institute of Biotechnology and Biomedicine at the Autonomous University of Barcelona, both belonging to the ICTS NANBIOSIS (nanbiosis.es) of the CIBER-BBN, have participated in the production of a novel Nanotoxin capable of selectively killing cancer cells which became resistant to chemotherapy. Development of cancer resistance frequently associates with the overexpression of the CXCR4 receptor. It is known that chemotherapy kills cancer[...]

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]

04 Feb

Design and engineering of tumor-targeted, dual-acting cytotoxic nanoparticles

In the frame of the collaboration of three units of NANBIOSIS, researchers of CIBER-BBN Groups proposed a strategy to simultaneously deliver anticancer drug pairs, composed by a tumor-targeted protein nanoparticle and an antiproliferative drug, with specific activ-ity for the same type of cancer. These three units are: NANBIOSIS U1 Protein Production Platform (PPP), at IBB-UAB, led by Toni Villaverde y Neus Ferrer NANBIOSIS U18 of Nanotoxicology Unit, at Institut de Recerca. Hospital de la Santa Creu i Sant Pau, led by Ramón Manques and Isolda Casanova, and NANBIOSIS U29 Oligonucleotide Synthesis Platform (OSP) at IQAC_CSIC, led by Ramón Eritja and[...]

27 Jan

Smart-4-Fabry final workshop

Next Wedneday, February 3, 2021 will take place the on-line event Smart-4-Fabry Final Workshop.   Smart-4-Fabry is a european project, coordinated by CIBER-BBN wich has been developed during four years. This project is a sign of cooperation at European level to boost nanomedicine development and translation to clinical stages. This project is also a clear example of the relevance of access to advanced research infrastructures as NANBIOSIS -ICTS. Four NANBIOSIS units have collaborated and contributed to Smart-4-Fabry development: U1 Protein Production Platform (PPP) at IBB-UABU3 Synthesis of Peptides Unit at IQAC-CSICU6 Biomaterial Processing and Nanostructuring Unit at ICMAB-CSICU20 In Vivo[...]

U1-Protein Production Platform - PPP
Read More

U6. Biomaterial Processing and Nanostructuring Unit

Ciber bbn

U6. Biomaterial Processing and Nanostructuring Unit

    • Scientific Director: Prof. Nora Ventosa ventosa@icmab.es 
    • Scientific Coordinator: Dr. Eduardo Pérez eperez2@icmab.es 
    • Entities: Instituto de Ciencia de Materiales de Barcelona ICMAB-CSIC
    • Address: Campus de UAB, 08193, Bellaterra, Barcelona, Spain
    • Phone: +34 935 801 853
    • Fax: +34 935 805 729
    • Web: ICMAB

ICMAB CSIC

Order request

Description

Located at the Instituto de Ciencia de Materiales de Barcelona (ICMAB-CSIC), in Barcelona, and under the coordination of Professor Jaume Veciana and Prof. Nora Ventosa, current directors of NANOMOL Group, which is a research group with wide expertise and recognized excellence in the synthesis, processing and study of molecular and polymeric materials with chemical, electronic, magnetic and biomedical properties.  It gathers several laboratories, perfectly equipped, to perform the mission of this facility: the development, characterization, and large-scale production of molecular biomaterials of therapeutic or biomedical interest, with controlled micro-, nano- and supramolecular structure. One example of Key-Enabling-Technology (KET) available in this unit is a simple one-step methodology, DELOS-SUSP, based on the use of compressed fluids (CF), such as CO2, to prepare particulate materials with precise and reproducible structural characteristics at micro-, nano- and supramolecular levels (size, shape, internal structural gradients, supra­molecular organization and crystalline purity). This example shows one of the singularities of this unit is that counts with CF–based plants at different scales, from mL to L, which allow process development by QbD and process scale-up.
The NANBIOSIS Unit 6 is also applying for the ISO9001 certification forstandard quality control system
 

 

 

U6. Services & Rates

Active projects

Title Fundin: Organism Call: Funding source Role
GA: 720942 SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry Unión Europea (Comisión Europea) H2020-NMBP-2016-2017 Coordinator
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Other projects

Ref Title Funding Organism Unit Role
PI15/00272 Design of intelligent nanoconjugates for the treatment of metastatic colorectal cancer. Instituto de Salud Carlos III Participant
H2020-MSCA-ITN-2014-642196 Integrated self-assembled SWITCHable systems and materials: towards responsive organic electronics - a multi-site innovative training action i-Switch Unión Europea H2020 Participant
2014 SGR 17 Consolidation Research Group: Molecular Nanociènciai Materials Orgànics (NANOMOL) Generalitat de Catalunya Participant
CTQ2013-40480-R Molecular Bio- and Electro-active materials for the improvement of health and social well-being (Be-Well) MICINN Participant
FP7-PEOPLE-2013-ITN nº 607721 Nanochemistry of molecular materials for 2-photon functional applications. Nano2Fun Unión Europea Participant
MAT2013-50036-EXP Cell Surface Vessel Engineering Using Dynamic Molecular Bioinfecting (DYNAMO) MINECO Participant
RTC-2016-4567-1 Nanocapsules containing active ingredients for the topical treatment of dermatological diseases (NANO4DERM) MINECO Participant
RTC-2014-2183-S Application of Quatsomes technology for the development of a new range of perfumed softeners with lower environmental impact MINECO Participant
201260E080 Self-assembly, Nanostructuring and Processing of Functional Organic Molecules and their Applications Ministerio de Ciencia e Innovación Participant
MAT2016-80826-R Molecular materials and supramolecular organizations for therapy, diagnosis and tissue engineering (MOTHER) MINECO Participant
RTC-2014-2207-1 TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases MINECO Participant

Publications

2016

  • Munoz-Gomez J.L., Monteagudo E., Lloveras V., Parella T., Veciana J., Vidal-Gancedo J.. Optimized polarization build-up times in dissolution DNP-NMR using a benzyl amino derivative of BDPA. RSC Advances. 2016;6(32):27077-27082.
  • Cordoba A., Hierro-Oliva M., Pacha-Olivenza M.A., Fernandez-Calderon M.C., Perello J., Isern B. et al. Direct Covalent Grafting of Phytate to Titanium Surfaces through Ti-O-P Bonding Shows Bone Stimulating Surface Properties and Decreased Bacterial Adhesion. ACS Applied Materials and Interfaces. 2016;8(18):11326-11335.
  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
  • Cano-Garrido O., Sanchez-Chardi A., Pares S., Giro I., Tatkiewicz W.I., Ferrer-Miralles N. et al. Functional protein-based nanomaterial produced in microorganisms recognized as safe: A new platform for biotechnology. Acta Biomaterialia. 2016;43:230-239.

News U6

19 Jul

Radical Dendrimers as Contrast Agents for Magnetic Resonance Imaging

José Vidal Gancedo, researcher from ICMAB-CSIC and CIBER-BBN is leading the project VIRADEN: “In vivo Studies of Radical Dendrimers as Contrast Agents for Magnetic Resonance Imaging“, one of the ICMAB Frontier Interdisciplinary Projects (FIP) 2021. The project aims to evaluate the new contrast agents for MRI based on organic radical dendrimers developed in his group, to substitute the currently used contrast agents based on toxic metals, with the final goal of obtaining useful contrast agents in the early detection of tumors José Vidal has explained NANBIOSIS participation in the project through Biomaterial Processing and Nanostructuring equipments of NANBIOSIS U6 counting wit[...]

14 Jul

Study of new liposomes for the delivery of enzymes through biological membranes

Judit Tomsen, researcher at Nanomol Group – NANBIOSIS U6 (ICMAB-CSIC and CIBER-BBN)  will defend her PhD thesis on Thursday, 15 July 2021, at 11 am in an hybrid session, from the ICMAB Seminar Room “Carles Miravitlles”.  Further information and Registration to attend the PhD Thesis defense via Zoom  at ICMAB-website. Supervisors: Nora Ventosa (Scientific Director of NANBIOSIS U6 Biomaterial Processing and Nanostructuring Unit and leader of Nanomol Group of CIBER-BBN- ICMAB-CSIC Elisabet González, Nanomol Group of CIBER-BBN – ICMAB-CSIC Abstract: Liposomes are lipid-based nanovesicles widely explored as nanocarriers for the transport of biomolecules or drugs of interest to the place of action, and for the development of new[...]

12 Jul

Jaume Veciana awarded by the Catalan Society of Chemistry with the Prize to the Scientific Excellence

Jaume Veciana Miró, Director of NANBIOSIS, has been awarded by the Catalan Society of Chemistry in its 2021 edition of Awards in research, education and dissemination with the Prize to the Scientific Excellence for his scientific career.[...]

06 Jul

New Nanomedicines for the topical treatment of complex wounds

Acute and chronic wounds are a growing global health problem. The incidence of non-healing chronic wounds has exponentially increased with the aging of the population and chronic diseases. It has been estimated that there is a 2% prevalence of chronic wounds in the general population, which is associated with an annual estimated cost of more than US$50 billion. Biomaterial-based treatments are helpful in improving small-sized and uncomplicated ulcers. Biologic molecules, named epidermal growth factors (EGFs) have demonstrated potent therapeutic efficacy along with limited side effects, however, exogenous EGF is rapidly cleared from the topical application site. Jaume Veciana, Nora Ventosa[...]

26 Mar

A new european infrastructure will facilitate the transfer of nano-pharmaceuticals from the lab to the clinic

Launch of the cross-european PHOENIX project, which will provide a new infrastructure available to research laboratories, SMEs and start-ups to facilitate the transfer of nano-pharmaceuticals from the laboratory to clinical practice. PHOENIX will have a duration of 4 years and a total budget of 14.45 million euros. Two CSIC Institutes, ICMAB (CSIC) and INMA (CSIC-UNIZAR), and one CSIC spin-off, Nanomol Technologies, participate in the project, will count with the expertise of NANBIOSIS unit 6 (from CIBER-BBN and ICMAB-CSIC), led by Nora Ventosa. PHOENIX is an innovation project funded by EU’s Horizon2020 Framework Programme aimed to provide services for the development, characterization, testing,[...]

26 Feb

A more effective nanomedicine has been developed for the treatment of Fabry rare disease.

28 February: International Rare Disease Day This is one of the major achievements of the European Smart4Fabry project, which is now coming to an end after four years of work.The results have been made possible by nanotechnology and the approach developed could be applied to other drugs in the future.The new drug improves on current treatments and helps reduce costs and improve patients’ quality of life. Barcelona, 26 February 2021.- The advance of nanomedicine opens up new possibilities in the development of drugs, such as the one recently developed for the rare disease Fabry, with improved efficacy compared to existing[...]

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]

27 Jan

Smart-4-Fabry final workshop

Next Wedneday, February 3, 2021 will take place the on-line event Smart-4-Fabry Final Workshop.   Smart-4-Fabry is a european project, coordinated by CIBER-BBN wich has been developed during four years. This project is a sign of cooperation at European level to boost nanomedicine development and translation to clinical stages. This project is also a clear example of the relevance of access to advanced research infrastructures as NANBIOSIS -ICTS. Four NANBIOSIS units have collaborated and contributed to Smart-4-Fabry development: U1 Protein Production Platform (PPP) at IBB-UABU3 Synthesis of Peptides Unit at IQAC-CSICU6 Biomaterial Processing and Nanostructuring Unit at ICMAB-CSICU20 In Vivo[...]

U6-Biomaterial Processing and Nanostructuring Unit
Read More

U10. Drug Formulation

Ciber bbn

U10. Drug Formulation

    • Scientific Director: Prof. José Luis Pedraz joseluis.pedraz@ehu.es
    • Scientific Coordinator: Dr. Idoia Gallego Garrido idoiagallego@hotmail.com
    • Entities: Universidad del País Vasco (UPV/EHU)
    • Address: Pharmacy & Pharmac. Technology Lab.; Facultad de Farmacia, C/Paseo de la Universidad 7, 01006 Vitoria-Gasteiz (Spain)
    • Phone: +34 653593042
    • Fax: +34 945 013040
    • Web: NANOBIOCEL UPV/EHU

UPV-EHU

Order request

Description

Located at the Faculty of Pharmacy, University of the Basque Country (UPV), Campus of Vitoria, is led by Prof. José Luis Pedraz and consists of large laboratories for: cell culture, chromatography equipment, sample preparation and characterization and one specific for scale preparation of pharmaceutical formulations. This Unit has the capacity to design and evaluate dosage forms both classical and new dosage forms of biotech drugs, DNA, RNA and vaccines using different methodologies based on micro and nano-medicine. The latter methodology based on the microencapsulation of cells, peptides, proteins, and in general of biotech products, as well as the development and design of non-viral vectors for gene therapy, is one of the biggest singularities of this unit. It counts with the most advanced equipment for micro and nano encapsulation.

The aim of the Unit is to determine experimentally all the variables needed to develop an optimal formulation and work instructions for preparing final pharmaceutical products.

The pharmaceutical technology applied to drug development involves the selection of materials and procedures that can be adapted to different processes that lead to specific pharmaceutical forms. To do that, the Unit counts with the most advanced equipment to cover the development for all the steps of the process.

One of the singularities of this Units is that is GLP certified by the Spanish Medicament Agency

U10. Services & Rates

Active projects

Title Fundin: Organism Call: Funding source Role
RTC-2016-4770-1 Development of a new bioadhesive for the treatment of Pterigium. Biotape
Ministerio de Economía, Industría y Competitividad (MINECO) Retos Colaboración 2016 Partner
RTC-2016-5451-1 Development of Bioprinting and Bioink systems for cartilage and bone repair
Ministerio de Economía, Industria y Competitividad (MINECO) Retos Colaboración 2016 Partner
GA: 783132 POSITION-II “A pilot line for the next generation of smart catheters and implants”
Electronic Component Systems for European Leadership Joint Undertaking (JU) - ECSEL JU H2020-ECSEL-2017-1-IA-two-stage Partner
GA: 645991 DRIVE – Diabetes-Reversing Implants for Enhanced viability and long-term efficacy Unión Europea (Comisión Europea) H2020-NMP-2014-two-stage Partner
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Other projects

Ref Title Funding Organism Unit Role
RTC-2016-4770-1 DEVELOPMENT OF A NEW BIOADHESIVE FOR PTERIGIUM SURGERY. BIOTAPE MINISTERIO DE ECONOMIA, INDUSTRIA Y COMPETITIVIDAD. Participant
RTC-2016-5451-1 DEVELOPMENT OF BIOIMPRESSION SYSTEMS AND BIOTINES FOR THREE-DIMENSIONAL CARTILAGE AND BONE REGENERATION MINISTERIO DE ECONOMIA, INDUSTRIA Y COMPETITIVIDAD. Participant
RTC-2015-3303-1 Lipid solid nanoparticles for subcutaneous administration of antitumor marine compounds - UNDERLIPIDS MINISTERIO DE ECONOMIA Y COMPETITIVIDAD

Publications

2016

  • Grijalvo S., Puras G., Zarate J., Pons R., Pedraz J.L., Eritja R. et al. Nioplexes encapsulated in supramolecular hybrid biohydrogels as versatile delivery platforms for nucleic acids. RSC Advances. 2016;6(46):39688-39699.
  • Moreno-Sastre M., Pastor M., Esquisabel A., Sans E., Vinas M., Fleischer A. et al. Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis. International Journal of Pharmaceutics. 2016;498(1-2):263-273.
  • Moreno-Sastre M., Pastor M., Esquisabel A., Sans E., Vinas M., Bachiller D. et al. Stability study of sodium colistimethate-loaded lipid nanoparticles. Journal of Microencapsulation. 2016;33(7):636-645.
  • Garcia-Orue I., Gainza G., Gutierrez F.B., Aguirre J.J., Evora C., Pedraz J.L. et al. Novel nanofibrous dressings containing rhEGF and Aloe vera for wound healing applications. International Journal of Pharmaceutics. 2016;:-.
  • Ojeda E., Puras G., Agirre M., Zarate J., Grijalvo S., Eritja R. et al. The role of helper lipids in the intracellular disposition and transfection efficiency of niosome formulations for gene delivery to retinal pigment epithelial cells. International Journal of Pharmaceutics. 2016;503(1-2):115-126.
  • Ojeda E., Puras G., Agirre M., Zarate J., Grijalvo S., Eritja R. et al. The influence of the polar head-group of synthetic cationic lipids on the transfection efficiency mediated by niosomes in rat retina and brain. Biomaterials. 2016;77:267-279.

News U10

27 Jul

Characterization of encapsulated porcine cardiosphere-derived cells for cardiac regeneration.

Researchers of NANBIOSIS U10 Drug Formulation unit of CIBER-BBN and UPV/EHU and NANBIOSIS U14 Cell Therapy unit and U24 Medical imaging unit at CCMIJU have participated in a research that proposes the use of encapsulated cardiosphere-derived cells (CDC), obtained from heart tissue, as regenerative cell therapy. “The encapsulation of the cells has been carried out [...]

07 Jul

Ibane Abasolo new Scientific Director of unit 20 of NANBIOSIS

Ibane Abasolo, the Scientific Coordinator of NANBIOSIS U20 of the CIBER-BBN at the Vall d’Hebron Research Institute (VHIR), has been appointed new Scientific Director, replacing Simó Schwartz, who has recently assumed the Directorate of the Blood and Tissue Bank of Catalonia. With her, there are 11 women who are Scientific Directors of NANBIOSIS units (46%), [...]

04 Mar

Reversing pulmonary fibrosis has been achieved in murine models with peptide-loaded nanoparticles

A new study with participation of NANBIOSIS Unit 10 Drug Formulation unit of CIBER-BBN and UPV/EHU, has succeeded in preventing and reversing pulmonary fibrosis in experimental models with PLGA / PEI nanoparticles loaded with the GSE4 peptide. These results are the first step to study its possible antifibrotic effect in patients with idiopathic pulmonary fibrosis [...]

26 Jan

New Center for Research in Advanced Pharmaceutical Development

The NanoBioCel Research group, led by Jose Luis Pedraz, from CIBER-BBN and UPV/EHU, group that coordinates the Unit U10 Drug Formulation of NANBIOSIS -ICTS, together with the Provincial Council of Álava and the Center for Technological Research and Development TECNALIA, have launched last Thursday, January 21, the new Center for Research in Advanced Pharmaceutical Development, [...]

28 Dec

Non-viral mediated gene therapy in human cystic fibrosis airway epithelial cells recovers chloride channel functionality

Researchers of CIBER-BBN Units of NANBIOSIS: U29 Oligonucleotide Synthesis Platform (OSP) at IQAC_CSIC, led by Prof. Ramón Eritja and U10 Drug Formulation, at UPV-EHU, led by Prof José Luis Pedraz, are coauthors of an article published by International Journal of Pharmaceutics. Gene therapy strategies based on non-viral vectors are currently considered as a promising therapeutic option [...]

21 Nov

Moore4Medical a project to accelerate innovation in electronic medical devices

The NanoBioCell group, led by Prof. Jose Luis Pedraz, participates in the European project Moore4medical. A project to accelerate innovation in emergencing medical devices with open tecnhology platforms. The NanoBiocel group, will focus on the lyophilization process of biopharmaceuticals and their use in microfluidic devices The NanoBiocel research group of the University of the Basque [...]

19 Nov

Ainhoa González Pujana, NANBIOSIS U10, 2019 best doctoral thesis award by the Bioaraba Research Health Institute

The Bioaraba Health Research Institute has awarded Ainhoa ​​González Pujana, a researcher at NanoBioCell and the Nanbiosis Platform through the U10 Drug Formulation (from CIBER-BBN and UPV-EHU), the award for the best doctoral thesis 2019 at the XXI Bioaraba Research and Innovation Conference, held last November 5 in Vitoria-Gasteiz. Along with the recognition, the award [...]

13 Nov

How to delay vision loss in hereditary retinal dystrophies? Looking for the most effective and economical pharmacological nanotherapy

Researchers from the CIBER-BBN and NANBIOSIS are participating in a new project that aims to achieve the most effective, specific and economical pharmacological nanotherapy that allows delaying the death of retinal cells and subsequent loss of vision in hereditary retinal dystrophy. retinitis pigmentosa, regardless of the genetic defect causing the disease. In this project, coordinated [...]

11 Nov

Laura Saenz del Burgo, NANBIOSIS U10, award for the best emerging researcher at the XXI Bioaraba Research and Innovation Conference

The CIBER-BBN researcher at the University of the Basque Country (UPV-EHU), Laura Saenz del Burgo, received, within the framework of the XXI Bioaraba Research and Innovation Conference, the award for the “Best Emerging Researcher 2020”. The researcher of the NanoBioCel group of the UPV / EHU, who belongs to the CIBER BBN and the U10 [...]

10 Nov

Regenerating ankle joints with collagen- and gelatine-based implants

 TRIANKLE is an EU Project to develop regenerative therapies for ankel injuries in which participate NanoBioCell Group and NANBIOSIS U10 Drug Formulation unit (from CIBER-BBN and UPV/EHU), led by José Luis Pedraz. The main objective is to reduce the time of recovery down to 50% andincrease the functionality ratios up to 10-15%. Research consortium [...]

U10-Drug Formulation
Read More